Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FF EAI Robotics Ecosystem Inc.RTTR · Entity 7776 | Director | January 21, 2020 | April 23, 2020 |
| OmniAb, Inc.OABI · Entity 5294 | Director · President and CEO | April 07, 2026 | April 08, 2026 |
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FF EAI Robotics Ecosystem Inc.
Report date January 21, 2020 · Filed April 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 138,635 |
Ending reported balance
After 2020-04-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-01-21 · Conversion · Acquired 76,923 · Balance 100,174 F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date. Row 2 · 2020-04-10 · Grant · Acquired 38,461 · Balance 138,635 F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.30 | Direct | 0 |
Reported balance
After 2020-01-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-21 · Conversion · Disposed 100 · Balance 0 F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date. |
| Warrant Shares (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2023-11-05 | Direct | 0 |
Reported balance
After 2020-04-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-04-10 · Disposition to issuer · Disposed 38,461 · Balance 0 F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date.
F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended.
OmniAb, Inc.
Report date April 07, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,420,492 |
Ending reported balance
After 2026-04-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-07 · Exercise / conversion · Acquired 36,459 · Balance 4,439,736 F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-04-07 · Sale · Disposed 19,244 · Balance 4,420,492 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 309,376 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Exercise / conversion · Disposed 36,459 · Balance 309,376 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Viking Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 135,186 |
Ending reported balance
After 2026-01-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-01-02 · Exercise / conversion · Acquired 16,000 · Balance 148,036 Row 2 · 2026-01-02 · Sale · Disposed 16,000 · Balance 132,036 F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2026-01-02 · Grant · Acquired 3,150 · Balance 135,186 F2: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 · Expires 2026-01-04 | Direct | 0 |
Reported balance
After 2026-01-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-02 · Exercise / conversion · Disposed 16,000 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.42 · Expires 2036-01-02 | Direct | 20,400 |
Reported balance
After 2026-01-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-02 · Grant · Acquired 20,400 · Balance 20,400 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LIGAND PHARMACEUTICALS INC
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,187 |
Reported balance
After 2022-11-01 transaction · row 1
1 source rowRow 1 · 2022-11-01 · Disposition to issuer · Disposed 20,304 · Balance 162,187 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.68 · Expires 2032-05-05 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 34,214 · Balance 0 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
OmniAb Operations, Inc.
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 212,362 |
Reported balance
After 2022-11-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-01 · Grant · Acquired 26,193 · Balance 212,362 F1: Includes 16,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F2: Includes 166,493 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 212,362 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05 | Direct | 60,878 |
Reported balance
After 2022-11-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-01 · Grant · Acquired 60,878 · Balance 60,878 F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-01 · Disposition to issuer · Disposed 60,878 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $41.82 · Expires 2024-02-12 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-01 · Disposition to issuer · Disposed 55,222 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2025-02-10 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-01 · Disposition to issuer · Disposed 35,258 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.21 · Expires 2026-02-11 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-11-01 · Disposition to issuer · Disposed 22,660 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $56.41 · Expires 2027-02-24 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-11-01 · Disposition to issuer · Disposed 21,271 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $89.36 · Expires 2028-03-02 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-11-01 · Disposition to issuer · Disposed 17,711 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $66.30 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-11-01 · Disposition to issuer · Disposed 29,861 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $53.77 · Expires 2030-02-13 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-11-01 · Disposition to issuer · Disposed 29,012 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $99.75 · Expires 2031-02-03 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-11-01 · Disposition to issuer · Disposed 11,475 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 16,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.
F2: Includes 166,493 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9.
F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022.
F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.
F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
F6: The stock option is fully vested and exercisable.
F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter.
F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter.
F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantCommon Stock | 1,305,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035050 · doc4.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,305,350 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F2 · shares: Includes 176,076 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F3 · shares: Includes 264,760 earn-out shares subject to forfeiture provisions described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb Operations, Inc. NONE · Entity 122629 | Disposition to issuerStock Option · Derivative | 11,475 | Not disclosed Strike: $99.75 | Not disclosed |
DisclosureSEC source: 0000899243-22-035048 · doc4.xml · derivative · entry 12 FOEHR MATTHEW W · CIK 0001237556 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,475 shares Expires 2031-02-03 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F9 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb Operations, Inc. NONE · Entity 122629 | Disposition to issuerStock Option · Derivative | 29,012 | Not disclosed Strike: $53.77 | Not disclosed |
DisclosureSEC source: 0000899243-22-035048 · doc4.xml · derivative · entry 11 FOEHR MATTHEW W · CIK 0001237556 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,012 shares Expires 2030-02-13 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F8 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb Operations, Inc. NONE · Entity 122629 | Disposition to issuerStock Option · Derivative | 29,861 | Not disclosed Strike: $66.30 | Not disclosed |
DisclosureSEC source: 0000899243-22-035048 · doc4.xml · derivative · entry 10 FOEHR MATTHEW W · CIK 0001237556 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,861 shares Expires 2029-02-11 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F7 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb Operations, Inc. NONE · Entity 122629 | Disposition to issuerStock Option · Derivative | 17,711 | Not disclosed Strike: $89.36 | Not disclosed |
DisclosureSEC source: 0000899243-22-035048 · doc4.xml · derivative · entry 9 FOEHR MATTHEW W · CIK 0001237556 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,711 shares Expires 2028-03-02 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb Operations, Inc. NONE · Entity 122629 | Disposition to issuerStock Option · Derivative | 21,271 | Not disclosed Strike: $56.41 | Not disclosed |
DisclosureSEC source: 0000899243-22-035048 · doc4.xml · derivative · entry 8 FOEHR MATTHEW W · CIK 0001237556 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,271 shares Expires 2027-02-24 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb Operations, Inc. NONE · Entity 122629 | Disposition to issuerStock Option · Derivative | 22,660 | Not disclosed Strike: $48.21 | Not disclosed |
DisclosureSEC source: 0000899243-22-035048 · doc4.xml · derivative · entry 7 FOEHR MATTHEW W · CIK 0001237556 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,660 shares Expires 2026-02-11 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb Operations, Inc. NONE · Entity 122629 | Disposition to issuerStock Option · Derivative | 35,258 | Not disclosed Strike: $31.62 | Not disclosed |
DisclosureSEC source: 0000899243-22-035048 · doc4.xml · derivative · entry 6 FOEHR MATTHEW W · CIK 0001237556 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,258 shares Expires 2025-02-10 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb Operations, Inc. NONE · Entity 122629 | Disposition to issuerStock Option · Derivative | 55,222 | Not disclosed Strike: $41.82 | Not disclosed |
DisclosureSEC source: 0000899243-22-035048 · doc4.xml · derivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,222 shares Expires 2024-02-12 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3 · shares: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb Operations, Inc. NONE · Entity 122629 | Disposition to issuerStock Option · Derivative | 60,878 | Not disclosed Strike: $50.96 | Not disclosed |
DisclosureSEC source: 0000899243-22-035048 · doc4.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,878 shares Expires 2032-05-05 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F5 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb Operations, Inc. NONE · Entity 122629 | GrantStock Option · Derivative | 60,878 | $0.00 Strike: $50.96 | $0.00 |
DisclosureSEC source: 0000899243-22-035048 · doc4.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,878 Underlying: Common Stock · 60,878 shares Expires 2032-05-05 F5 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb Operations, Inc. NONE · Entity 122629 | Disposition to issuerCommon Stock | 212,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035048 · doc4.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F4 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb Operations, Inc. NONE · Entity 122629 | GrantCommon Stock | 26,193 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-035048 · doc4.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,362 F1 · shares: Includes 16,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F2 · balance_after: Includes 166,493 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9. F3 · balance_after: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. Read SEC document |
| November 01, 2022 Filed Apr 23, 2024 21:44 UTC Amendment | OmniAb, Inc. OABI · Entity 5294 | GrantCommon Stock | 1,431,618 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001846253-24-000014 · wk-form4a_1713908655.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,296,665 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F2 · shares: This amendment is being filed to correct a Form 4 filed on November 3, 2022, which inadvertently understated the number of shares beneficially held by the Reporting Person following the transaction reported by 126,268 shares. The number reported in column 4 represents the correct number of shares acquired by the Reporting Person as of November 1, 2022, which included (1) 176,076 restricted stock units and (2) 391,030 earn-out shares. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F3 · balance_after: Represents the number of shares beneficially held by the Reporting Person as of the date of this filing, as adjusted for the administrative error identified in footnote 2. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 21:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 9,137 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000092 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,491 Read SEC document |
| May 13, 2022 Filed May 13, 2022 23:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 2,500 | $82.76 | $206,909.50 |
DisclosureSEC source: 0000886163-22-000062 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,354 Read SEC document |
| May 05, 2022 Filed May 10, 2022 00:10 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 34,214 | $0.00 Strike: $90.68 | $0.00 |
DisclosureSEC source: 0000886163-22-000055 · edgardoc.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,214 Underlying: Common Stock · 34,214 shares Expires 2032-05-05 F1 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 3-year, 9-month period measured from the date of grant, 12-1/2% after three months, then 1/48th of the Option Shares per month thereafter. The date of grant is 05/05/2022. Read SEC document |
| May 02, 2022 Filed May 3, 2022 20:12 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | PurchaseCommon Stock, par value $0.00001 per share | 45,000 | $2.47 | $111,195.00 |
DisclosureSEC source: 0001209191-22-026674 · doc4.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,250 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 01:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,090 | $123.68 | $134,811.20 |
DisclosureSEC source: 0000886163-22-000023 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,854 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/03/2021. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 01:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,222 | $123.68 | $151,136.96 |
DisclosureSEC source: 0000886163-22-000023 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,944 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 01:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,234 | $123.68 | $152,621.12 |
DisclosureSEC source: 0000886163-22-000023 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,166 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 3,188 | $113.68 | $362,411.84 |
DisclosureSEC source: 0000886163-22-000011 · edgardoc.xml · nonDerivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,400 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,937 | $113.68 | $220,198.16 |
DisclosureSEC source: 0000886163-22-000011 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,588 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 7,396 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000011 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,525 F2 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 03/09/2020 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2021. On January 26, 2022, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 5,604 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000011 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,129 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/29/2019 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2021. On January 26, 2022, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:08 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-22-001980 · doc4.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2032-01-03 Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:54 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,028 | $0.00 Strike: $100.38 | $0.00 |
DisclosureSEC source: 0000886163-21-000132 · edgardoc.xml · derivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,348 Underlying: Common Stock · 1,028 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/24/2017. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:54 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,160 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0000886163-21-000132 · edgardoc.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,160 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:54 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 11,160 | $163.02 | $1,819,255.21 |
DisclosureSEC source: 0000886163-21-000132 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,525 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.41 to $166.38, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:54 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 11,160 | $21.92 | $244,627.20 |
DisclosureSEC source: 0000886163-21-000132 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:54 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,028 | $100.38 | $103,190.64 |
DisclosureSEC source: 0000886163-21-000132 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 20:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,142 | $0.00 Strike: $85.79 | $0.00 |
DisclosureSEC source: 0000886163-21-000121 · edgardoc.xml · derivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,938 Underlying: Common Stock · 1,142 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/11/16. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 20:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,840 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0000886163-21-000121 · edgardoc.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,160 Underlying: Common Stock · 8,840 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 20:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,142 | $85.79 | $97,972.18 |
DisclosureSEC source: 0000886163-21-000121 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 20:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 8,840 | $109.67 | $969,506.67 |
DisclosureSEC source: 0000886163-21-000121 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,355 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.06 to $111.00, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 20:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 8,840 | $21.92 | $193,772.80 |
DisclosureSEC source: 0000886163-21-000121 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2021 Filed Jun 10, 2021 20:57 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | PurchaseCommon Stock, par value $0.00001 per share | 20,000 | $5.69 | $113,800.00 |
DisclosureSEC source: 0001209191-21-039521 · doc4.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,250 Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 20:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,755 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0000886163-21-000077 · edgardoc.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,358 Underlying: Common Stock · 1,755 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/10/15. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 20:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,755 | $56.26 | $98,736.30 |
DisclosureSEC source: 0000886163-21-000077 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 20:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-21-000077 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,600 F1 · price: Charitable gift to a third party. Read SEC document |
| March 22, 2021 Filed Mar 26, 2021 01:30 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | OtherWarrants (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001209191-21-023130 · doc4.xml · derivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2021-04-13 Read SEC document |
| March 22, 2021 Filed Mar 26, 2021 01:30 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | OtherCommon Stock, par value $0.00001 per share | 20,000 | $1.50 | $30,000.00 |
DisclosureSEC source: 0001209191-21-023130 · doc4.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 23:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,222 | $172.46 | $210,746.12 |
DisclosureSEC source: 0000886163-21-000042 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,100 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 23:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,235 | $172.46 | $212,988.10 |
DisclosureSEC source: 0000886163-21-000042 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,322 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 23:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 641 | $172.46 | $110,546.86 |
DisclosureSEC source: 0000886163-21-000042 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,557 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 03/02/2018. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 22:03 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $74.42 | $0.00 |
DisclosureSEC source: 0000886163-21-000029 · edgardoc.xml · derivative · entry 6 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,210 Underlying: Common Stock · 1,000 shares Expires 2024-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/12/14. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 22:03 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 44,547 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0000886163-21-000029 · edgardoc.xml · derivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 44,547 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 22:03 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 44,547 | $176.86 | $7,878,582.42 |
DisclosureSEC source: 0000886163-21-000029 · edgardoc.xml · nonDerivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,198 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.52 to $180.89, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 22:03 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 44,547 | $21.92 | $976,470.24 |
DisclosureSEC source: 0000886163-21-000029 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 22:03 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,000 | $74.42 | $74,420.00 |
DisclosureSEC source: 0000886163-21-000029 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.